anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic disseminated candidiasis, often referred to as hepatosplenic candidiasis (HSC), is an infection due to Candida spp. that mainly involves the liver and spleen. HSC occurs mostly in patients with profound and prolonged neutropenia, which is more often seen in patients with hematologic malignancies. Despite an appropriate antifungal prophylaxis, the incidence of HSC in France might be closed to 5% in patients suffering from acute leukemia. Early and adequate diagnosis and treatment of HSC are crucial, as treatment delays can negatively affect the prognosis of the underlying condition. Current guidelines recommend a 6-month duration treatment. Prolonged treatments up to 6 months are frequent, leading to antifungal toxicity and cost increase. Preliminary study by our team has already assessed F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) as a diagnostic tool for HSC. 18F-FDG PET scan could be helpful in the diagnosis, follow-up and therapy strategy of HSC, helping to stop antifungal treatment. Other molecular, immunological and serological tools have to be developed in order to avoid hepatic biopsies. Actually, mycological evidence of infection is found in only 20% of the cases. The pathogenesis of HSC is also not well understood, but it is believed that it may be due to an unbalanced adaptive immune response that leads to an exacerbated inflammatory reaction, resulting in an Immune Reconstitution Inflammatory Syndrome (IRIS). In that context, a better understanding of the disease pathophysiology and of the potential genetic susceptibility could have an impact on therapy strategy. For example, new approaches such as the use of adjuvant high-dose corticosteroids have been shown beneficial. This study is the first step to improve HSC diagnosis and therapy strategy.
Free fatty acids will be elevated approximately 2-fold for 48 hours by intravenous infusion of Intralipid and heparin. 15 abdominally obese insulin resistant, but otherwise healthy, non-diabetic men will be studied on three occasions each, in random order, 4 weeks apart. We have chosen to study abdominally obese, insulin resistant individuals rather than lean healthy controls because we have previously shown that these individuals are more susceptible to lipotoxicity and we are therefore more likely to see differences between the interventions if differences indeed exist. Informed written consent will be obtained from all participants in accordance with the guidelines of the Human Subjects Review Committee of the University Health Network.

Subjects will be hospitalized in the Metabolic Investigation Unit (MIU) of the Toronto General Hospital for each of their three studies, which will be performed in random order 4 to 6 weeks apart. On one occasion a saline control study will be performed, on a second occasion Intralipid (20% solution @ 40ml/hr) and heparin (250u/hr) will be infused for 48 hours as previously described and on a third occasion NAC will be administered orally concurrently with the Intralipid and heparin. The dose of NAC will be the same as that recommended for acetaminophen overdose. An initial loading dose of 140mg/kg NAC followed by a maintenance dose of 70mg/kg every 4 hours during the 48 hour infusion of Intralipid and heparin. On day three, testing of glucose-stimulated insulin secretion (GSIS) will occur as outlined below. Subjects will be provided with an isocaloric diet consisting of 50% calories derived from carbohydrates, 30% fat and 20% protein during the 48 hour infusions and will fast from midnight for the testing of pancreatic beta cell function on day three.
BACKGROUND: Pembrolizumab (PEM), an immune checkpoint inhibitor (ICI), is often used for triple-negative breast cancer, but can also be used to treat solid tumors that exhibit high microsatellite instability (MSI-High). However, patients with breast cancer rarely have MSI-High, the use of PEM in such cases in clinical practice is uncertain due to lack of sufficient supporting data. Here, we report the case of a premenopausal woman in who received PEM for MSI-High luminal-type breast cancer.
CASE PRESENTATION: A 40-year-old premenopausal Asian woman was diagnosed with stage IIA (T2N0M0) breast cancer and had an Oncotype DX recurrence score of 38. After surgery, she received 4 courses of chemotherapy with docetaxel and cyclophosphamide. After 3 months of tamoxifen therapy, the patient complained of abdominal pain due to right iliac metastasis, and biopsy of the metastatic lesion showed of luminal type; she was sequentially treated with fulvestrant, a CDK4/6 inhibitor, and an anticancer drug (TS1), but over the next year, metastasis to the bone and para-aortic lymph nodes increased. Tumor was MSI-High; PEM was started, and after three courses, bone metastases were reduced, para-aortic lymph node metastases resolved, opioids were discontinued, and the patient returned to society; PEM was administered for 1 year with no worsening of bone metastases on imaging. Asymptomatic brain metastasis less than 1 cm was detected and gamma knife was performed. Six months after completion of PEM, the patient is working with no new lesions.
CONCLUSION: We report a case of luminal-type breast cancer with bone metastases and MSI-High, which was treated with PEM and showed a rapid therapeutic response.
Patients and methods: The investigators studied 2 groups of patients electively scheduled for laparoscopic cholecystectomy. The study group included 10 patients that were ventilated by high frequency jet ventilation (HFJV). In the control group (16 patients) the investigators used the standard intermittent positive pressure ventilation (IPPV). Both groups were matched according to clinical and hemodynamic parameters. Intra-ocular pressure was measured by a senior ophthalmologist that was blinded to the ventilation technique. Laparoscopic surgery was done as usual, and the intra-peritoneal pressure was automatically set on 14 mmHg. Statistical significance was considered whenever P value was less than 0.05.

The investigators anticipate that the use of HFJV during laparoscopic operations under PP may prevent increased intra-ocular pressure that accompanies increased intra-abdominal pressure under conventional ventilation (IPPV).
Antimicrobial resistance is a critical public health concern, necessitating the exploration of alternative treatments. While antimicrobial peptides (AMPs) show promise, assessing their toxicity using traditional wet lab methods is both time-consuming and costly. We introduce tAMPer, a novel multi-modal deep learning model designed to predict peptide toxicity by integrating the underlying amino acid sequence composition and the three-dimensional structure of peptides. tAMPer adopts a graph-based representation for peptides, encoding ColabFold-predicted structures, where nodes represent amino acids and edges represent spatial interactions. Structural features are extracted using graph neural networks, and recurrent neural networks capture sequential dependencies. tAMPer's performance was assessed on a publicly available protein toxicity benchmark and an AMP hemolysis data we generated. On the latter, tAMPer achieves an F1-score of 68.7%, outperforming the second-best method by 23.4%. On the protein benchmark, tAMPer exhibited an improvement of over 3.0% in the F1-score compared to current state-of-the-art methods. We anticipate tAMPer to accelerate AMP discovery and development by reducing the reliance on laborious toxicity screening experiments.
PCT No. PCT/DE94/00314 Sec. 371 Date Sep. 12, 1995 Sec. 102(e) Date Sep. 12, 1995 PCT Filed Mar. 17, 1994 PCT Pub. No. WO94/21240 PCT Pub. Date Sep. 29, 1994New superparamagnetic particles useful in medicine for destroying tumors, increasing immunity and diagnosing conditions are disclosed. For that purpose, very small superparamagnetic single-domain particles are aggregated and protected against further aggregation by chemical bonding of reactive stabilizer substances on the surface of the superparamagnetic particles. These new particles thus consist of stable, decomposable aggregates with a particle size in a range between 10 and 1000 nanometers and a defined behavior in a magnetic field. The aggregates consist of several small superparamagnetic single-domain particles of iron oxide, iron mixed oxide or iron, with a particle size in a range between 3 and 20 nanometers, bearing on their surface chemically bound organic substances from the group comprising the phosphate, diphosphate, polyphosphate, thiophosphate, phosphonate or group containing polyalkylene glycols, phosphate group containing nucleotides, their oligomers or polymers, as well as phosphate group containing carbohydrates, which may present further binding sites. Both the new disclosed superparamagnetic aggregates and reactive stabilizer substances may be active substances.
NEW MATERIAL:A dextran (salt) having activation pat derived from carboxylation carried out using 2-4 valent aliphatic polybasic acid or reactive derivative thereof and having form partially substituting H of carboxylic acid by a group expressed by formula I (L<1> and L<2> are amine, monodentate coordinate amine or together bidentate coordinate amine; Y is anion ligand) and/or form substituting H of 2 carboxylic acids bonded to carbon atom. of activated part or adjacent carbon atom. by a group expressed by formula II. USE:An anticancer agent. PREPARATION:For example, dextran is reacted with 2-4 valent aliphatic polybasic acid or reactive derivative thereof (e.g. succinic anhydride) to activate the dextran and the activated dextran derivative is reacted with cis platinum (II) complex to provide dextran-cis platinum (II) complex composite.
Behavioral physiotherapeutic approach in combination with neck specific exercises from a structured well defined frame of exercises and how to treat the patient. 2 times a week for 3 months.
The aim of this study is to determine whether a novel software virtual reality (VR) program provided during transition from periop to the procedure room and anesthesia induction reduces preoperative anxiety, and induction compliance in pediatric patients. This study aims to specifically monitor and measure the anxiety of patients as they arrive at the preoperative suite, when parting from their parents for transportation to the procedure room, and at induction of anesthesia. Compliance during anesthesia induction will also be monitored. Participants will be randomized to one of two groups. Group 1 will receive standard care during their surgery. Group 2 will receive standard care and distraction with a novel virtual reality software program. We hypothesize that anxiety will be reduced, and anesthesia compliance will improve for participants in Group 2.
The Albert Einstein College of Medicine (Einstein), the HIV Center for Clinical and Behavioral Studies (HIV Center), the Montefiore Medical Center Department of Obstetrics and Gynecology (OBGYN, Implementing Partner) and the Alliance for Positive Change (Alliance, Implementing and Community Partner) will compare two healthcare models that integrate PrEP into OBGYN services. Both models are acceptable standards of care and represent evidence-based approaches to the provision of care. This study is the first example of comparing these interventions in a head-to-head, comparative-effectiveness model. Both groups will benefit from maintained access, enhanced assessment with the PrEP screening tool, and physicians will all receive an evidence-based PrEP education seminar with supporting materials and ongoing access to education and resources. MODEL 1, OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the "purview paradox"; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling. The goal is that PrEP be provided by a trusted provider with whom the patient has an ongoing relationship. In MODEL 2, NP-PC PrEP, all the same provisions and practices present in Model 1 will be present however, a telehealth opportunity with a Nurse Practitioner (NP) will be provided. A skilled and PrEP-trained NP will deliver PrEP services via telemedicine visits
INTRODUCTION: The optimal temperature of irrigation solution in patients undergoing PCNL is still unclear. Accordingly, this study aims to investigate the effects of different irrigation solution temperatures (cold/room temperature irrigation fluid versus warm/body temperature fluid). Our primary endpoint was hypothermia rate. Secondary outcomes were shivering rate, mean temperature decrease, mean patient final temperature, blood loss, and operative time.
EVIDENCE ACQUISITION: This systematic review was conducted in accordance with PRISMA guidelines. Multiple databases were searched in November 2023. Among 299 studies screened, eight were selected for full-text review, resulting in four randomized clinical trials that fit inclusion criteria and desired outcomes. Studies selection and data extraction were performed by multiple reviewers and a random-effects model was used for pooling of data.
EVIDENCE SYNTHESIS: The primary outcome, hypothermia rate, showed a significant statistical difference between groups, occurring less frequently in the experimental group (35-37 ºC) than in the cold/room temperature irrigation group (RR 0.64;95%CI 0.46, 0.89; P<0.008; I2=33%). Secondary outcomes such as shivering rate (RR 0.46; 95%CI 0.31, 0.67; P<0.0001; I2=0%) and mean final temperatures (MD 0.43; 95%CI 0.12, 0.75; I2=82%) also showed statistically significant differences between groups, favoring the irrigation with heated fluid.
CONCLUSIONS: There was a decreased rate of hypothermia and shivering among patients undergoing PCNL with warm irrigation fluid. Mean final temperatures were also higher in the experimental group. As to blood loss, mean hemoglobin decrease showed no statistically significant difference between groups, prompting further investigation of the influence of Irrigation solution temperature on blood loss volume.
A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
The invention relates to a substance which is extracted from giant knotweed for curing diabetes mellitus and complicating diseases. By using the substance extracted from the giant knotweed, the medicine for curing diabetes mellitus and the complicating diseases can be produced effectively, and the treatment problems of diabetes mellitus and the complicating diseases are solved. The substance is coarse powder of the giant knotweed and can be prepared through the following steps: putting the giant knotweed in a round flask, adding 6 times quantity of grain alcohol to soak the giant knotweed; refluxing and extracting and filtering the grain alcohol, and the reflux extraction and the filtering are carried out to medical slag which is added with the grain alcohol which is 6 times of the medical slag. The filtrate water are combined for two times, the filtrate water is decompressed for recycling the grain alcohol, and the filtrate water is added in the pretreatment and reborn macro pore adsorption resin column; the resin column is elutriated with distilled water until the eluate is colorless, and the resin column is elutriated with the grain alcohol, the mass concentration of which is 70 percent, the eluate is collected till the eluate does not contain any component of anthraquinone, and the grain alcohol is recycled, and the total anthraquinone which is the extracted substance of the giant knotweed can be gained when the eluate is volatilized on the water bath. The invention has the advantages that the preparation method of the product is scientific, the operation is easy, the quality of the total anthraquinone which is the preparation substance is good, the purity quotient is high and the effect is good. The substance can be used for preparing the medicine which is used for curing diabetes mellitus and the complicating diseases, and the substance which benefits mankind is a creative of the development and the application of the giant knotweed medicine.
NEW MATERIAL:The compound of formula I (R<1> is H or alkyl; A is saturated 5- or 6-membered monocyclic hetero-ring which may contain N or O atom other than the N atom shown in the formula, wherein the N or O atom may have alkyl or hydroxyalkyl group). EXAMPLE:alpha-Isocyanoacetic acid morpholinamide. USE:An agricultural chemical. alpha-Isocyanoacetic acid piperazinamide is useful also as an antiphlogistic agent. PROCESS:The compound of formula I can be prepared by reacting the amine of formula II with the alpha-isocyanofatty acid ester of formula III (R<2> is ester residue). The reaction is carried out preferably in a proper solvent (e.g. methanol) at about room temperature, using about 1.5-3mol of the compound of formula IIper 1mol of the compound of formula III.
Clinics randomized to NPT-PLA will also define their CRC screening workflow via a checklist and preset I2 implementation protocol but will be trained initially then receive monthly support to facilitate a "Participatory Learning in Action" (PLA) session. NPT-PLA i-teams will identify barriers and supports to I2 implementation, and use Normalization Process Theory (NPT) constructs to guide identification, selection and ordering of action steps to progress implementation e.g. "(before taking the step) does everyone understand the step to be taken, does everyone who needs to act 'buy in', (during implementation of the step) is everyone who needs to act actually taking action to complete the step, (after the step is taken) did taking the step have the intended impact, if not what happened?" . NPT-PLA I-teams can adapt the I2 implementation protocol to fit their context, including when and how patients are presented with I2, to maximize I2 implementation and CRC screening completion.
Subjects will have 3 treatment sessions at weeks 0, 4, and 8 and a final live assessment visit at week 14. Approximately two syringes of CaHA will be injected per side of the buttocks (at sites with cellulite dimpling) during each of the three treatment sessions.
Genes encoding five immunodeterminant protein antigens of the leprosy parasite Mycobacterium leprae have been isolated. The gene encoding the M. leprae 65kD antigen was sequenced and a lambda gt11 gene sublibrary was constructed with fragments of the gene. Recombinant DNA clones producing specific antigenic determinants were isolated using monoclonal antibodies and the sequences of their insert DNAs were determined with a rapid primer extension method. Amino acid sequences for six different epitopes of the M. leprae protein were elucidated. A peptide containing sequences for one of these epitopes, which is unique to M. leprae, was synthesized and shown to bind the appropriate monoclonal antibody; The approach described here can be used to elucidate rapidly protein epitopes that are recognized by antibodies or T cells. In addition, the well-characterized M. leprae antigens can be used in prevention, diagnosis and treatment of leprosy.
Participants enrolled in this group received a pericapsular nerve group block with 20 ml of 0.2% ropivacaine. The block was performed with a 100 mm needle, inserted with an in-plane lateral to medial approach. Operator used a low frequency curvilinear probe.
1. Prevention of Endometrial Hyperplasia: A postmenopausal women with a uterus who is taking estrogens should take a single daily dose of 200 mg progesterone capsules at bedtime for 12 continuous days per 28-day cycle. 
  2. Secondary Amenorrhea: Progesterone capsules may be given as a single daily dose of 400 mg at bedtime for 10 days. 
  3. Progesterone capsules are to be taken at bedtime as some women become very drowsy and/or dizzy after taking progesterone capsules. In a few cases , symptoms may include blurred vision, difficulty speaking, difficulty walking, and feeling abnormal. If you experience these symptoms, discuss them with your healthcare provider right away.



If you experience difficulty in swallowing progesterone capsules, it is recommended that you take your daily dose at bedtime with a glass of water while in the standing position.
Risk Summary

Based on the mechanism of action, TECVAYLI may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available data on the use of TECVAYLI in pregnant women to evaluate for a drug associated risk. No animal reproductive or developmental toxicity studies have been conducted with TECVAYLI. Teclistamab-cqyv causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, teclistamab-cqyv has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus. 

TECVAYLI is associated with hypogammaglobulinemia, therefore, assessment of immunoglobulin levels in newborns of mothers treated with TECVAYLI should be considered.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
The invention discloses an external liniment for relieving onychia lateralis. The liniment is prepared from the following raw materials by weight: 1-5 parts of Meixliuncliic, 1-5 parts of XongkSems and 3-15 parts of camellia oil. The above raw materials are weighed according to amounts by weight. Preferably, the Meixliuncliic and XongkSems are local wild fresh herbs, and camellia oil is special superior camellia oil prepared from traditional technology of Dong nationality. Meixliuncliic and XongkSems are mixed, supplemented with the camellia oil and soaked for half a month, and the liniment should be sealed to avoid light for standby. The Chinese herbal medicines in the invention complement with each other, have the advantages of clearing heat, detoxicating, relieving swelling, killing pain, killing worm and dehumidifying, can repair the nail beds and beautify and brighten the nails. The raw materials of the invention have the advantages of convenience, simplexes, effectiveness and low cost, have no toxic or side effect. The external liniment is suitable for clinical popularization; and many patients who cannot be cured by other treatment or recurrent patients after nail excision can receive a satisfactory effect by using this method; therefore, the invention has considerable development prospects.